Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
Bologna, Italy
General hospital in Bologna
Via Giuseppe Massarenti, 9, 40138 Bologna BO
1,535 Beds
About Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
The Sant’Orsola-Malpighi Polyclinic is a university and public hospital. The Polyclinc is the largest hospital in Italy, and the first of the four public hospitals of the city of Bologna. The Polyclinic has approximately 1,535 beds and 5,153 employees.
There are 1,535 beds in Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
IRCCS Azienda Ospedaliero-Universitaria di Bologna
3
Daiichi Sankyo, Inc.
1
NovoCure Ltd.
1
Seagen Inc.
1
Clinical Trials at Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
During the past decade, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on
average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
2013-04-03
2025-04-03
Active, not recruiting
1,487
Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET
2014-09-01
2030-12-01
Active, not recruiting
1,507
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2017-03-08
2022-08-12
Completed
1,301
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
2019-03-22
2023-09-01
Active, not recruiting
540
Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies
2019-06-20
2021-09-01
Unknown status
60
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
2020-12-04
2030-12-31
Recruiting
1,600
Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
2020-10-12
2023-12-01
Recruiting
150
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "IRCCS Azienda Ospedaliero-Universitaria di Bologna" with 3 trials
sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "NovoCure Ltd." with 1 trials sponsored and "Seagen Inc."
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii"
#1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "German Breast Group" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Azienda ULSS 12 Veneziana" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were
collaborators in the rest 13 trials.
Clinical Trials Conditions at Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" are
"Breast Cancer" (4 trials), "Ovarian Cancer" (3 trials), "Cervical Cancer" (1 trials), "Fallopian Tube Cancer" (1 trials) and "Gynecologic Cancer" (1 trials). Many other conditions were trialed in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" in a lesser frequency.
Clinical Trials Intervention Types at Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
Most popular intervention types in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" are "Drug" (6 trials), "Other" (2 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (2 trials), "Paclitaxel" (2 trials), "Arm B, tumor markers assessment" (1 trials), "Atezolizumab Placebo" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
The vast majority of trials in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" are
5 trials for "Female" genders and 4 trials for "All" genders.
Clinical Trials Status at Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
Currently, there are NaN active trials in "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii".
undefined are not yet recruiting,
3 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".